Iyoda Masayuki, Ito Jyun, Ajiro Yuriko, Nagai Hisako, Uchida Junichi, Honda Hirokazu, Kuroki Aki, Shibata Takanori, Kitazawa Kozo, Sugisaki Tetsuzo
Department of Nephrology, Showa University School of Medicine, Tokyo, Japan.
Nihon Jinzo Gakkai Shi. 2005;47(7):828-33.
Herein we describe the case of a patient with focal segmental glomerulosclerosis (FSGS) following polycythemia vera (PV) on whom hemodialysis was started 7 years later. A 66-year-old woman who had been treated for PV with hydroxyurea and phlebotomy for three years was referred to our hospital because of nephrotic syndrome. Renal biopsy performed at her local hospital revealed FSGS. Although she had received prednisolone at an initial dose of 45 mg/day, no significant improvement of proteinuria was achieved. The dose of prednisolone was tapered because the second renal biopsy revealed sclerosing glomerulopathy. We considered that FSGS was associated with PV because renal hemodynamic alterations in PV could result in FSGS as in any other secondary FSGS and there was no proteinuria at the initial detection of PV. On January 29, 1999, she developed massive proteinuria (9.6 g/day) and the findings of the third renal biopsy worsened in comparison with that of the first renal biopsy. Thereafter, hydroxyurea or ranimustine was used in treating PV at an outpatient clinic. However severe thrombocytosis was difficult to control, and progressive renal dysfunction finally necessitated hemodialysis on January 18, 2005. In conclusion, physicians should be aware of the risk of progressive renal failure in patients with FSGS following PV, particularly in patients with persistent thrombocytosis.
在此,我们描述了一例真性红细胞增多症(PV)后发生局灶节段性肾小球硬化(FSGS)的患者病例,该患者在7年后开始进行血液透析。一名66岁女性因肾病综合征被转诊至我院,她曾接受羟基脲和放血疗法治疗PV三年。在当地医院进行的肾活检显示为FSGS。尽管她最初接受了45毫克/天的泼尼松龙治疗,但蛋白尿并未得到明显改善。由于第二次肾活检显示肾小球硬化病变,泼尼松龙剂量逐渐减少。我们认为FSGS与PV有关,因为PV中的肾血流动力学改变可能导致FSGS,如同其他继发性FSGS一样,且在最初检测到PV时并无蛋白尿。1999年1月29日,她出现大量蛋白尿(9.6克/天),第三次肾活检结果与第一次相比恶化。此后,在门诊使用羟基脲或雷莫司汀治疗PV。然而,严重的血小板增多症难以控制,最终肾功能进行性恶化,于2005年1月18日不得不进行血液透析。总之,医生应意识到PV后发生FSGS的患者有发生进行性肾衰竭的风险,尤其是持续性血小板增多症患者。